Table 3. Risk of asthma exacerbation in T2-high ACO and T2-low ACO.
| Acute exacerbation | Model 1: unadjusted | Model 2: age, BMI adjusted | Model 3: age, BMI, blood eosinophil adjusted | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Crude OR | 95% CI | P value | Adjusted OR | 95% CI | P value | Adjusted OR | 95% CI | P value | |
| Low IgE ACO | Reference | Reference | Reference | ||||||
| High IgE ACO | 0.47 | 0.05–4.43 | 0.507 | 0.52 | 0.05–5.33 | 0.579 | 0.54 | 0.05–5.78 | 0.503 |
| Atopy (−) ACO | Reference | Reference | Reference | ||||||
| Atopy (+) ACO | 3.72 | 1.14–12.17 | 0.03 | 3.87 | 1.09–13.68 | 0.036 | 4.19 | 1.01–17.42 | 0.049 |
| Low blood eosinophil ACO | Reference | Reference | Reference | ||||||
| High blood eosinophil ACO | 0.84 | 0.33–2.12 | 0.715 | 0.8 | 0.3–2.12 | 0.653 | 1.47 | 0.19–11.35 | 0.713 |
All adjusting variables were measured at the baseline visit. Bold-styled values denote significant ones.
T2, type 2; ACO, asthma–chronic obstructive pulmonary disease overlap; BMI, body mass index; OR, odds ratio; CI, confidence interval; IgE, immunoglobulin E.